Karl Anders Knutsson, Paola Noemi Genovese, Giorgio Paganoni, Oriella Ambrosio, Giulio Ferrari, Arianna Zennato, Michela Caccia, Madeleine Cataldo, Paolo Rama
{"title":"角膜交联治疗圆锥角膜患者的安全性和有效性:长期结果。","authors":"Karl Anders Knutsson, Paola Noemi Genovese, Giorgio Paganoni, Oriella Ambrosio, Giulio Ferrari, Arianna Zennato, Michela Caccia, Madeleine Cataldo, Paolo Rama","doi":"10.3390/medsci11020043","DOIUrl":null,"url":null,"abstract":"<p><p>The present study evaluated the effectiveness and safety of corneal collagen cross-linking (CXL). A total of 886 eyes with progressive keratoconus were enrolled in a retrospective cohort study in a tertiary care university hospital. CXL was performed using a standard epithelium-off Dresden protocol. Visual outcomes, maximum keratometry (Kmax), demarcation line measurements, and complications were recorded. Visual outcomes and keratometric data were analyzed in a subgroup comprising 610 eyes. Uncorrected distance visual acuity (UDVA) improved from 0.49 ± 0.38 LogMAR to 0.47 ± 0.39 LogMAR (<i>p</i> = 0.03, n = 610) three years after the procedure, while corrected distance visual acuity (CDVA) improved from 0.15 ± 0.14 LogMAR to 0.14 ± 0.15 LogMAR (<i>p</i> = 0.007, n = 610). A significant reduction of Kmax from 56.28 ± 6.10 to 54.98 ± 6.19 (<i>p</i> < 0.001, n = 610) was observed three years after CXL. In five eyes (0.82%, 5/610) keratoconus progression continued after CXL. Three eyes were retreated successfully with documented refractive and topographic stability after five years. In the 35 eyes that completed 10 years of follow-up, mean visual acuity and topographic parameters remained stable. In conclusion, CXL is a safe and effective treatment for avoiding keratoconus progression. Long-term data are encouraging, supporting a high safety profile for this procedure.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"11 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302271/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety and Efficacy of Corneal Cross-Linking in Patients Affected by Keratoconus: Long-Term Results.\",\"authors\":\"Karl Anders Knutsson, Paola Noemi Genovese, Giorgio Paganoni, Oriella Ambrosio, Giulio Ferrari, Arianna Zennato, Michela Caccia, Madeleine Cataldo, Paolo Rama\",\"doi\":\"10.3390/medsci11020043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study evaluated the effectiveness and safety of corneal collagen cross-linking (CXL). A total of 886 eyes with progressive keratoconus were enrolled in a retrospective cohort study in a tertiary care university hospital. CXL was performed using a standard epithelium-off Dresden protocol. Visual outcomes, maximum keratometry (Kmax), demarcation line measurements, and complications were recorded. Visual outcomes and keratometric data were analyzed in a subgroup comprising 610 eyes. Uncorrected distance visual acuity (UDVA) improved from 0.49 ± 0.38 LogMAR to 0.47 ± 0.39 LogMAR (<i>p</i> = 0.03, n = 610) three years after the procedure, while corrected distance visual acuity (CDVA) improved from 0.15 ± 0.14 LogMAR to 0.14 ± 0.15 LogMAR (<i>p</i> = 0.007, n = 610). A significant reduction of Kmax from 56.28 ± 6.10 to 54.98 ± 6.19 (<i>p</i> < 0.001, n = 610) was observed three years after CXL. In five eyes (0.82%, 5/610) keratoconus progression continued after CXL. Three eyes were retreated successfully with documented refractive and topographic stability after five years. In the 35 eyes that completed 10 years of follow-up, mean visual acuity and topographic parameters remained stable. In conclusion, CXL is a safe and effective treatment for avoiding keratoconus progression. Long-term data are encouraging, supporting a high safety profile for this procedure.</p>\",\"PeriodicalId\":74152,\"journal\":{\"name\":\"Medical sciences (Basel, Switzerland)\",\"volume\":\"11 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302271/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical sciences (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/medsci11020043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci11020043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
本研究评价了角膜胶原交联(CXL)的有效性和安全性。在一所三级保健大学医院进行了一项回顾性队列研究,共纳入了886只进行性圆锥角膜。CXL采用标准的上皮脱落德累斯顿方案进行。记录视力、最大角膜曲率(Kmax)、分界线测量值和并发症。在一个由610只眼睛组成的亚组中分析视力结果和角膜测量数据。术后3年未矫正距离视力(UDVA)由0.49±0.38 LogMAR改善至0.47±0.39 LogMAR (p = 0.03, n = 610),矫正距离视力(CDVA)由0.15±0.14 LogMAR改善至0.14±0.15 LogMAR (p = 0.007, n = 610)。术后3年Kmax由56.28±6.10降至54.98±6.19 (p < 0.001, n = 610)。5只眼(0.82%,5/610)在CXL后圆锥角膜继续恶化。3只眼术后5年屈光稳定性和地形稳定性均有记录。在完成10年随访的35只眼中,平均视力和地形参数保持稳定。综上所述,CXL是一种安全有效的避免圆锥角膜进展的治疗方法。长期数据令人鼓舞,支持该手术的高安全性。
Safety and Efficacy of Corneal Cross-Linking in Patients Affected by Keratoconus: Long-Term Results.
The present study evaluated the effectiveness and safety of corneal collagen cross-linking (CXL). A total of 886 eyes with progressive keratoconus were enrolled in a retrospective cohort study in a tertiary care university hospital. CXL was performed using a standard epithelium-off Dresden protocol. Visual outcomes, maximum keratometry (Kmax), demarcation line measurements, and complications were recorded. Visual outcomes and keratometric data were analyzed in a subgroup comprising 610 eyes. Uncorrected distance visual acuity (UDVA) improved from 0.49 ± 0.38 LogMAR to 0.47 ± 0.39 LogMAR (p = 0.03, n = 610) three years after the procedure, while corrected distance visual acuity (CDVA) improved from 0.15 ± 0.14 LogMAR to 0.14 ± 0.15 LogMAR (p = 0.007, n = 610). A significant reduction of Kmax from 56.28 ± 6.10 to 54.98 ± 6.19 (p < 0.001, n = 610) was observed three years after CXL. In five eyes (0.82%, 5/610) keratoconus progression continued after CXL. Three eyes were retreated successfully with documented refractive and topographic stability after five years. In the 35 eyes that completed 10 years of follow-up, mean visual acuity and topographic parameters remained stable. In conclusion, CXL is a safe and effective treatment for avoiding keratoconus progression. Long-term data are encouraging, supporting a high safety profile for this procedure.